Introduction
The age-adjusted incidence of prostate cancer in African American (black) males, is 50% higher than in Caucasian (white) men, and African-American (black) men have the highest incidence of prostate cancer in the world. 1 Furthermore, the mortality rate is 55.1/100 000 for black men compared to 24.7/100 000 for white men, a two-fold difference, indicating that prostate cancer is a public health problem in this population. 2 The etiology for these racial differences in prostate cancer clinical manifestations is unknown; hormonal, nutritional, genetic, behavioral and socioeconomic status (SES) factors have all been implicated. 3 Despite the etiological debate, there is emerging knowledge that focused education can improve early detection efforts in this high-risk group. Furthermore, there is now a large body of literature about prostate-speci®c antigen (PSA) and ®ne-tuning its use in African-American men. This current report will update these important areas that are critical to urologic practice.
The concept of race and prostate cancer
The concept of race is considered a social de®nition taking into account historical, social and economic events not a biological classi®cation. 5 Some have argued for abandoning race in variable analysis because it has no biologic meaning and is medicalization of racism. 6, 7 Recently, Brawley and Freeman contend that equal treatment yields equal outcome among patients with the same stage of disease regardless of race. 8 They further argue that race is not a biologic category and that the concept of biologically more aggressive tumors in blacks be abandoned. However, the fact remains that African-American or black men have a greater risk of being diagnosed with prostate cancer and their disease is usually more advanced and potentially more aggressive. The simple goal of research in this area is to improve outcomes for these men. Realizing that race may be an indicator of economic status, cultural preferences or misunderstandings, and genetic susceptibility for cancer behavior and development, the pragmatic mission is to understand these contributing factors to prostate cancer in this highrisk group and eliminate the observed disparity.
Knowledge and attitudes
Conventional wisdom has been that African-American men are less knowledgeable and more reluctant to undergo prostate cancer screening than other groups; however, a number of recent studies have shed more light on this issue. Robinson et al conducted focus groups on prostate cancer screening in middle and lower socioeconomic groups of African-Americans. 9, 10 Among middle socioeconomic participants there was a willingness to undergo screening and individuals possessed reasonable knowledge; however, among the low socioeconomic groups, there were many misconceptions and myths about the etiology and mortality of cancer. Fewer of the low socioeconomic men knew that prostate cancer was a greater problem in blacks than whites and many were unaware of rectal examination or blood tests. There was concern in the low socioeconomic men that blacks are`used as guinea pigs' in reference to the Tuskegee syphilis trials. There was also fear of hearing bad news and misconceptions of surgery causing cancer to spread and rectal examination having homosexual implications. 9 The authors felt that culturally relevant education and establishing a patient ± provider relationship of trust and respect were needed.
Abbott et al also conducted a study of 944 Caucasian and African-American men regarding prostate knowledge. 11 At baseline, the black men were signi®cantly less likely to identify early symptoms of prostate cancer than white men, but after an educational session there were no racial differences except that blacks still felt that pain' was the ®rst symptom of prostate cancer. Despite this improvement in knowledge with education, Bennett et al have documented the impact of literacy. 12 In 212 lowincome men, blacks were almost twice as likely to present with metastatic prostate cancer (49.5% vs 35.9%; P`0.05) and have literacy less than sixth grade level (52.3% vs 8.7%; P`0.001) compared to whites and literacy but not race was associated with stage. Guidry et al have studied educational materials for prostate cancer and found that only 40% are culturally sensitive, taking into account low literacy and other readability factors. 13 Myers et al 14 and Weinrich and associates 15 have documented that African-American peer-education and tailored behavioral intervention can improve prostate education and early detection efforts. In this light, the recently reported Detroit Education and Early Detection (DEED) study of Powell and associates must be detailed. 16 The DEED program conducted prostate cancer education and screening in the Detroit area, focusing on African-American churches, and screened 1105 black men between 1993 and 1995. 16 Eighty-®ve of the 1 105 men (8%) had a PSA value of greater than 4.0 ng/ml and 36 cancers (3.2% overall, 42% of men with elevated PSA) were detected. Although a success, the program was only able to reach the middle income (median $30 943) and educated (average of`some college'). The lost to followup rate (11.7%) and biopsy refusal rate (4.7%) in DEED was felt to be not signi®cantly higher than screening programs in white populations. In the screened DEED men who underwent radical prostatectomy, the rate of organ-con®ned disease was 65%, which is higher than historic controls of black surgical patients. 16, 17 Considering the relatively high detection rate in this young (mean age 54.9 y) group of black middle socioeconomic men, further efforts to reach the low socioeconomic and even younger men seem most warranted. 18, 19 Screening for prostate cancer in African-American men Early detection for prostate cancer has been practiced for many years in the form of digital rectal examination (DRE). However, over the last decade with the advent of PSA, the topic of prostate cancer screening has become a hotly contested issue. 20, 21 A full discussion of populating-based screening is beyond the scope of this current report; however, the key question is whether screening black men should be considered`population-based' or treated more like`case-®nding' in a high-risk group similar to those men with a family history of the disease. The latest guidelines from the American College of Physicians 22 and the American Cancer Society 23 dictate against routine screening but recommend apprising men of the pros and cons of testing and letting the wellinformed individual decide. While theoretically sound, in practical terms many physicians do not take the time or have the time for such counseling and the screening may or may not be done based on the bias of the practice. Furthermore, in light of new`stage migration' data in the PSA era 24, 25 and even one randomized trial reporting a bene®t to population-based screening, 26 the pros and con discussion is controversial. Speci®cally, should clinicians give the`bene®t-of-doubt' that screening may improve long-term outcome or emphasize the uncertainty. The dilemma is more dif®cult for African-American men: we want to lessen the disparity with early detection but we currently lack de®nite date on screening ef®cacy in this high-risk group. In the DEED program, Powell et al found that screened African-American men had a higher likelihood of organ-con®ned, nonadvanced prostate cancer. 16 Furthermore, encouraging data from the Radiation Therapy Oncology Group (RTOG), 27 US Military 28 and Veterans Administration, 29 suggest that if black men are afforded the same access, are diagnosed with early stage disease, and receive similar care, the outcomes disparity may be minimized or eliminated. Screening and early detection issues in African-American men remain. The proper age to initiate testing is debated. While Powell et al feel that screening in black men should start at an earlier age, 30 the proper age between 35 ± 45 and even up to age 50 is not known and deserves study. The issue of PSA in African-American men is widely debated and is discussed below.
PSA in black men
In 1992, Vjayakumar and associates were the ®rst to report that black American men with newly diagnosed prostate cancer referred for radiotherapy had higher PSA levels than their white counterparts. 31 A number of other preliminary early reports also suggested that blacks had higher PSA. 32, 33 These early reports lacked proper multivariate adjustment for stage, grade are and socioeconomic status. In 1995, our group reported on 541 consecutive men with newly diagnosed prostate cancer and showed that, even with adjustment for tumor grade, age and clinical stage, black men had higher PSA. 34 In this same study, we took a subsequent consecutive cohort of 91 black and white men who underwent a radical prostatectomy and had whole-mount processing of their prostate with careful tumor volume assessment. 34 What we found startled us; even in our military equal-access health care system, the black men had much higher tumor volumes overall and within each clinical stage. This within-stage tumor volume disparity was primarily responsible for the racial difference in PSA and PSA was a surrogate for bigger tumors in black men.
Since this report, a large number of studies have con®rmed that black American males, in general, have higher PSA values than white males. In particular, a number a recent studies from Vjayakumar and colleagues suggest that the racial disparity in PSA is primarily due to socioeconomics. 35 ± 36 In one investigation, blacks and whites who had similar insurance had similar PSA values; however, among Medicare bene®ciaries blacks had higher PSAs. 35 Conversely, in another study they did ®nd that African-American men without prostate cancer had higher PSA and PSA density than whites or Hispanics after adjustment for age and prostate volume. 36 In a follow-up study of the same cohort, race was not an independent predictor of PSA in multivariable analysis and they concluded that PSA differences are due to sociological rather than biological causes. 37 In a multicenter registration study of the Radiation Therapy Oncology Group (RTOG), they also found that African-American men with nonmetastatic prostate cancer had higher PSA than whites and that household income, education and insurance alone or in combination did not completely account for this racial difference. 38 Finally, Vijayakumar et al ®rst described the`Will Rogers pheno-menon' in prostate cancer, that is, stage migration in the PSA-era for both blacks and whites. 39 Speci®cally, they documented a 12.2% per year decline in median PSA values in newly diagnosed African-American men and concluded that widespread PSA screening was ameliorating the racial difference in PSA, proving the socioeconomic hypothesis.
In contrast to this, our group recently updated our study of three-dimensional measured tumor volume and prediagnosis PSA values in a large cohort of military health care bene®ciaries undergoing radical prostatectomy. 40 In 226 patients (155 whites and 46 blacks) treated between 1993 and 1997, blacks had signi®cantly higher PSA values at diagnosis despite multivariable adjustment for tumor volume, benign gland volume, age, pathological stage and Gleason grade. Even in an equal access health care system with careful adjustment for comprehensively measured exact tumor burden, the AfricanAmerican men had higher PSA, implying a biological basis. In a follow-up study, we also showed that this racial difference in PSA was not due to prostatitis or prostatic in¯ammation. 41 Conversely, Eastham et al found that it was more common for African-American men to exhibit in¯ammation on prostate biopsy. 42 Over time it could be possible that blacks exhibit more episodes of in¯ammation with more transient rises in PSA accounting for more prostate biopsies of African-American men with normal digital rectal examinations. 42 Still to be resolved as possible causes of higher observed PSA values in African-American men are greater amounts of high-grade prostatic intraepithelial neoplasia (PIN), 43 and higher PSA production or greater PSA`leakage' We do not believe that PIN is responsible in that PIN alone is not felt to bean source for PSA elevation. 44 Based on studies of serum testosterone and CAG repeats in the androgen receptor by race, 45, 46 we believe that androgen stimulation may be responsible for greater PSA production in blacks. This hypothesis, however, must await further study.
Proper use of PSA in African-American men
Despite the widespread use of PSA, until the late 1990s no data existed to document the value of PSA testing and ®ne tune' the test for the early and accurate diagnosis of prostate cancer in this population.
There was an urgent need to examine the proper PSÀ normal' for black men and over the last few years a number of groups have examined the clinical utility of PSA in this population. Studies in particular by Smith and Catalona and colleagues from Saint Louis have shed much light in this area. 47 ± 49 In their ®rst study of 17 157 white and 804 black men 50 y old, black men had a higher prevalence of elevated PSA ( 4.0 ng/ml, 13.1 vs 8.9%) and higher cancer detection rate (5.1 vs 3.2%). They also did not see a signi®cantly higher cancer stage in the black screening volunteers who were diagnosed compared to whites but they did not draw signi®cant volunteers from low SES zip code areas. In their second study, they found that a PSA b 4.0 ng/ml detected more cancer than digital rectal exam (DRE) for both blacks and whites. 48 Furthermore, the positive predictive value (PPV) for prostate cancer detection for both PSA and DRE was higher for blacks than whites (48 and 38% vs 38 and 22%). This study showed that the widely accepted PPV for PSA greater than 4.0 ng/ml of 25 ± 30% did not apply to African-American men who have a higher risk estimate of 36 ± 60%. In their most recent study, they lowered the threshold for PSA screening evaluation to 2.5 ng/ml and screened 14209 white men and 1004 black men 50 y old between 1995 and 1997. 49 Blacks were younger (60 vs 63; P 0.005) and presented with higher PSA (3.3 vs 3.1 ng/ml; P 0.03) and black race remained an independent predictor of prostate cancer controlling for age, total PSA, PSA density, percentage free PSA, and number of prior screening visits. They concluded that lowering the screening threshold to 2.5 ng/ml was rea-sonable, but felt that further study was needed to determine if this was the optimum cut-off point to screen African-American men.
Our group has also studied the ability of PSA to detect prostate cancer in both Caucasian and African-American men and developed age-adjusted PSA reference ranges for maximal cancer detection in this high-risk group of men. 50 In this study, between January 1991 and May 1995 serum PSA concentration was determined for 3475 men without clinical evidence of prostate cancer (1802 Caucasian, 1673 African-American) and 1783 men with the disease (1372 Caucasian, 411 African-American). All PSA examinations were performed using Abbott IMx assay (normal 0 ± 4 ng/ml) in a central, single laboratory. PSA concentration was analyzed as a function of age and race to determine operating characteristics of PSA for the diagnosis of prostate cancer. Serum PSA concentration correlated directly with age for both black and white men (r 0.40, P 0.001 for blacks and r 0.34, P 0.0001 for whites. African-American men had signi®cantly higher serum PSA concentrations than Caucasian men (P 0.0001 Figure 1 ). When sensitivity was plotted against 1-speci®city, the area under the receiver operator characteristic (ROC) curve was 0.91 for black men, and 0.94 for white men, indicating that the PSA test is an excellent early detection tool. For comparison, the Papanicolaou smear for cervical cancer, which is an accepted clinical screening test, has a ROC value of 0.70. When we calculated age-speci®c reference ranges by the identical methodology of Oesterling and colleagues used in their 1993 study of primarily Caucasian patients from Olmstead County, Minnesota, 51 we found very similar values for white men but higher values for black men. These ranges were 0 ± 2.4 ng/ml for black men aged 40 ± 49, 0 ± 6.5 ng/ml for men aged 50 ± 59, 0 ± 11.3 ng/ml for men aged 60 ± 69, and 0 ± 12.5 ng/ml for men aged 70 ± 79. We then tested these new ranges in our group of black men with prostate cancer to determine how these ranges would have performed if they had been used to detect their cancers. Unfortunately, these markedly higher ranges would have missed 41% of the cancers (only 59% sensitivity).
The reason these traditionally derived ranges performed so poorly is that they are simply the 95th percentiles of values in the black controls. Because there is more variability of PSA results in blacks without evidence of cancer, there is more skewness, which pushes the 95th percentile farther to the right (higher). This higher range, however, is not clinically useful. We therefore developed age-adjusted reference ranges for black men with prostate cancer, selecting PSA upper limits of normal by decade to maximize cancer detection. In other words, we developed reference ranges by decade in the men with prostate cancer by using the 5th percentile of PSA values. Only the lowest 5% of pre-diagnosis PSA values in the black men with cancer are`normal' and the remainder (95%) are above the normal (95% sensitivity).
We refer to these ranges as the Walter Reed/Center for Prostate Disease Research age-speci®c reference ranges for maximal cancer detection (Table 1 ). They maximize sensitivity (cancer detection) without undue loss of speci®city (false positive/unnecessary TRUS/biopsy). These values for maximal cancer detection for black and white men are compared to the traditional normal (0 ± 4 ng/ml) and the previously developed age-speci®c reference ranges in Table 2 . 
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Our age-and race-adjusted PSA reference ranges have been met with some criticism. Littrup has been concerned that the average reader will not realize that our reference ranges are based on men with prostate cancer and are designed for sensitivity of cancer detection, not speci®-city. 52 He feels that we should refer to the ranges as`agesensitive reference ranges'. Furthermore, he feels that our values are perhaps too complex and would favor only two PSA`normals' b 2.0 ng/ml for`high-risk men' and b 4.0 ng/ml for the`general' population. 53 He is also concerned that any of these presently derived decision points for PSA only address`cancer' or no`cancer', not de®ning a lower decision level for PSA in this high risk group to reduce their disproportionate mortality.
Most recently, Powell and colleagues have also been critical of the Walter Reed/CPDR PSA reference ranges for African-American men. 54 They studied 651 consecutive radical prostatectomy patients who had a pretreatment PSA value and were operated between 1991 and 1995. They found that disease stage and grade was similar or worse for blacks compared to whites at all PSA ranges. Their basic concern was that we should not have raised the threshold PSA level to prompt a prostate biopsy above that for Caucasian men at any age because black men are at higher risk for cancer and have historically presented when their disease was more advanced. They feel that using a lower PSA threshold in black men may lessen the disparity that currently exists. On one hand, I agree with them. In fact, I have proposed lower PSA reference ranges to increase the odds of curable cancer in black men. 55 The problem is that one would need to biopsy all black men with a PSA greater than approximately 1.0 ng/ml to provide a 95th probability of curable cancer. 55 This illustrates the dilemma of various PSA thresholds to prompt prostate biopsy Ð the lower the cut-off point the higher the sensitivity (fewer missed cancers at potentially more curable stages) and the higher the cut-off point the better the speci®city (fewer`unneces-sary' biopsies), but more missed cancers at potentially higher stages.
Despite Powell et al's 54 concern about our proposed age-adjusted PSA values, 50 I do not feel that they have proven their point. In my opinion, the important question is: is there any difference in stage, grade or outcomes in the range where the PSA cut-off points are disputed? Speci®cally, for men in their 50s is there a racial disparity between PSA of 3.5 and 4.0 ng/ml and between 3.5 and 4.5 ng/ml for men in their 60s. The authors found that African-American men had lower organ-con®ned rates than Caucasian men when the pretreatment PSA was between 4.1 and 7.9, but this is not relevant to the range that they are disputing ie between 3.5 and 4.5 Furthermore, they showed signi®cant racial disparity in PSArecurrence in men with PSA 4.0 and 10.0 but this is not relevant to the reference range debated between 3.5 and 5.5 ng/ml. Finally, their study did not address the ranges in question: 3.5 ± 4.0, 3.5 ± 4.5 and 3.5 ± 5.5 ng/ml. Their comparisons with all African-American men and Caucasian men above various PSA values are not valid. By including all subjects with PSAs above a certain cut-off point biases the analysis of survival. Speci®cally, if there are more African-American men with high PSAs, who obviously will have a lower DFS, it will bias the statistics. Unfortunately, they did not have suf®cient numbers of cases to adequately address whether any meaningful outcome differences by ethnicity were present in the narrow PSA cut-off point ranges that are debated.
As previously noted, our group is attempting to develop PSA reference ranges for curable prostate cancer in African-American men. 56 Using the criteria of curability after radical prostatectomy de®ned by Carter et al, from Johns Hopkins, 57 only 45% of contemporaryera black men who underwent a radical prostatectomy at our hospital were`curable'. 56 This compares to 74% for the predominantly white patients reported by Carter et al. 57 Furthermore, by pre-treatment PSA, Table 3 shows the striking racial differences in curability. Based on this, we are currently conducting a multicenter study to de®ne age-adjusted PSA reference ranges for curable prostate cancer using age, pre-treatment PSA value and only those men who meet the curable criteria.
Clinicians screening black (and white) men for prostate cancer currently have a wide choice of PSA thresholds to consider including the traditional 4.0 ng/ml for everyone, the Mayo Clinic age-adjusted ranges, 51 the Walter Reed/ Center for Prostate Disease Research ranges, 50 a 2.5 ng/ ml cut-off point along with percentage free PSA advocated by Catalona et al, 58 or the 2.0 ng/ml threshold advocated by Littrup from Wayne State for all AfricanAmerican men. 52 Perhaps more important than`splitting hairs' about these subtle differences in PSA level, the key factor may be initiating screening at a younger age (40 ± 45 y) and following through with periodic sequential testing during a window of opportunity (ie 40 ± 60 or 45 ± 65 y, as an example). Targeted screening for prostate cancer JW Moul
Despite the continuing controversy about the`exact' proper PSA by age and race, the most important concept, in my opinion, is recognizing that a PSA screening cut-off point of 4.0 ng/ml is probably too high for younger men, such as African-American men between 40 and 49 y of age. Bullock et al screened 214 black men between 40 and 49 y of age and found a prevalence of prostate cancer of 0.9% (2 out of 214) when a PSA of 4.0 ng/ml was used. 59 Interestingly, this prevalence increased to 5.6% (2 out of 36) when the black men also had a family history of prostate cancer. Conversely, Catalona et al from the same university, found that the cancer detection rate was 38% in a small group of 16 black men who had biopsy for PSA values between 2.6 and 4.0 ng/ml. 60 In a follow-up larger series, this same group found an even higher prevalence of 42% for African-American men with PSA between 2.6 and 4.0 ng/ml. 5 Our Department of Defense-funded Center for Prostate Disease Research (CPDR) has recently conducted three studies that illustrate that a PSA of 4.0 ng/ml is signi®-cantly higher than normal for young men. In 750 black and 750 white military members between the ages of 15 and 45 who had serum banked in the Department of Defense Serum Repository (DoDSR), the mean PSA values were 0.52 and 0.47 ng/ml, respectively. 61 The 95th percentile ranged from 1.16 to 1.38 ng/ml for the blacks strati®ed by decade of age (1.38 ng/ml in the 40 ± 49 group); for the whites the corresponding values were 0.71 ± 1.13 ng/ml. Based on this new data, even using a PSA value of 2.0 ng/ml as a cut-off point for both black and white men is considerably higher than these 95th percentile values.
Our second study is a prospective screening study of healthy of®cers enrolled in the US Army War College at Carlisle Barracks, PA and is a collaboration between CPDR and the Army Physical Fitness Research Institute. 62 Between 1997 and 1999, 602 otherwise healthy military of®cers (86.2% Caucasian) age 40 ± 49 y had a PSA test as part of a comprehensive health assessment at enrollment. In this primarily white cohort, only 10 of 602 (1.7%) had PSA 2.5 ng/ml and only 2 (0.5%) had PSA 4.0 ng/ml. All 10 men who had PSA 2.5 had sextant prostate biopsy and only one patient (0.17%) has been diagnosed with prostate cancer to date. The mean PSA value for the 601 men without cancer was 0.73 ng/ml and the 95th percentile (screening cut-off point) was 1.6 ng/ml. We are initiating a similar study in a non-commissioned of®cer military school to increase data on African American men between 40 and 49.
Our third study is a retrospective study of 1105 Students aged 30 ± 59 y, from the National Defense University, Fort McNair, Washington, DC between 1994 and 1999. 63 For men in the 30 ± 39, 40 ± 49, and 50 ± 59 age groups, the 95th percentile of PSA was 1.6, 2.3 and 2.7 ng/ ml, respectively. If 18 men (1.6%) who had PSA 4.0 were excluded, the corresponding PSA values are 1.6, 2.1 and 2.4, respectively. Unfortunately, this study did not have ethnic information, therefore, we could not stratify by race.
These three studies clearly illustrate that PSA values are very low for the vast majority of younger men, both black and white. Using a lower screening threshold below 4.0 ng/ml in men in their 40s (and perhaps 50s) would appear to be justi®ed.
Conclusions
African-American men are at higher risk for being diagnosed with prostate cancer, although the cause is unknown. Almost all ethnic comparisons to date have found that blacks present with more advanced prostate cancer and have higher mortality. Recent studies in the PSA era suggest that this disparity may be partially or completely eliminated by education, equal-access and similar screening compliance. In general, PSA values are higher in African-American men. While most of this difference is due to greater tumor burden in blacks, our research shows slightly higher PSA values in AfricanAmerican men even with age, grade and tumor volume taken into account. This difference may have implications for PSA screening reference ranges although the`exact' proper screening guidelines remain hotly debated. Based on current knowledge, I believe that using a lower PSA screening threshold of 2.0 ng/ml and educating and testing high-risk African-American men annually starting at age 40 is justi®ed. 64 
